hepatocellular carcinoma |
55 |
liver transplantation |
36 |
medical sciences |
28 |
hepatectomy |
22 |
gastroenterology |
19 |
surgery |
17 |
adult |
16 |
cirrhosis |
16 |
gastroenterology medical sciences |
16 |
liver resection |
16 |
recurrence |
16 |
survival |
16 |
liver transplant |
15 |
next-generation sequencing |
15 |
transarterial chemoembolization |
15 |
outcomes |
14 |
sorafenib |
14 |
child-pugh a |
13 |
hcc |
13 |
liver failure |
13 |
portal vein |
13 |
blood transfusion |
12 |
acute flare |
11 |
cancer staging |
11 |
cancer survival |
11 |
decompensation |
11 |
hepatocellular carcinoma (hcc) |
11 |
high-intensity focused ultrasound |
11 |
liver cancer |
11 |
meld |
11 |
ablation |
10 |
alpps |
10 |
bridging therapy |
10 |
living donor |
10 |
molecular biology |
10 |
molecular pathology |
10 |
morbidity |
10 |
new technology |
10 |
signaling |
10 |
11c-acetate |
9 |
cancer invasion |
9 |
contrast ct |
9 |
endocrinology |
9 |
hifu |
9 |
laparoscopic liver resection |
9 |
living donor liver transplantation |
9 |
milan criteria |
9 |
mortality |
9 |
non-invasive treatment |
9 |
pet/ct |
9 |
resection |
9 |
survival analysis |
9 |
acetic acid c 11 |
8 |
advanced cancer |
8 |
advanced hcc |
8 |
advanced hepatocellular carcinoma |
8 |
adverse events |
8 |
aged |
8 |
antiviral agents - adverse effects - therapeutic use |
8 |
bile ducts - surgery |
8 |
cadaver donor |
8 |
cancer recurrence |
8 |
cancer stem cells |
8 |
carcinoma, hepatocellular - complications/diagnosis - surgery |
8 |
carcinoma, hepatocellular - surgery - virology |
8 |
cardiac function |
8 |
child-pugh b |
8 |
colorectal cancer |
8 |
deceased donor liver transplantation |
8 |
disease severity |
8 |
elderly |
8 |
fluorodeoxyglucose f 18 |
8 |
gene mutation |
8 |
gist |
8 |
guanine - adverse effects - analogs and derivatives - therapeutic use |
8 |
hepatectomy - methods |
8 |
hepatitis b |
8 |
hepatitis b, chronic - complications - diagnosis - drug therapy - surgery |
8 |
immunotherapy |
8 |
liver cirrhosis - surgery - virology |
8 |
liver disease |
8 |
liver metastasis |
8 |
liver neoplasms - complications/diagnosis - surgery |
8 |
prevention |
8 |
rsk2 |
8 |
seroconversion (sc) |
8 |
stereotactic body radiation therapy |
8 |
thrombosis - diagnosis - etiology - surgery |
8 |
tki |
8 |
tyrosine-kinase inhibitor |
8 |
unresectable |
8 |
waiting list |
8 |
abdominal abscess |
7 |
abdominal bleeding |
7 |
abdominal surgery |
7 |
adjuvant therapy |
7 |
biliary anastomotic stricture |
7 |
body mass index |
7 |
cap |
7 |
cardiac surgery |
7 |
complication |
7 |
cytology and histology |
7 |
de novo hbv |
7 |
de novo hepatocellular carcinoma |
7 |
domino liver transplant |
7 |
entecavir |
7 |
experience |
7 |
extended criteria organ |
7 |
general surgery |
7 |
glycolysis |
7 |
graft-to-recipient weight ratio |
7 |
head of pancreas |
7 |
hepatitis b infection |
7 |
hepatitis b vaccination |
7 |
hypoxia |
7 |
icc |
7 |
indocyanine green clearance |
7 |
laparoscopy |
7 |
laparoscopy - statistics and numerical data |
7 |
limon |
7 |
liver biopsy |
7 |
liver cirrhosis |
7 |
living donor liver transplant |
7 |
long-term outcome |
7 |
long-term survival |
7 |
mafld |
7 |
medicine & public health |
7 |
metabolic syndrome |
7 |
model for end-stage liver disease |
7 |
nafld |
7 |
oncology medical sciences |
7 |
pediatric |
7 |
pfkfb |
7 |
portal vein resection |
7 |
prognosis |
7 |
ptbd |
7 |
pulse spectrophotometry |
7 |
radiofrequency ablation |
7 |
radiology and nuclear medicine pharmacy and pharmacology biology |
7 |
recurrent hcc |
7 |
retransplantation |
7 |
right liver graft |
7 |
right-lobe |
7 |
small-for-size syndrome |
7 |
survival outcomes |
7 |
thoracic surgery |
7 |
transthyretin |
7 |
val30ala |
7 |
vascular surgery |
7 |
vcte |
7 |
whipple operation |
7 |
acute pancreatitis |
6 |
acute-on-chronic liver failure |
6 |
adverse outcome |
6 |
aged, 80 and over |
6 |
anastomosis, surgical |
6 |
antiviral therapy |
6 |
bile leak |
6 |
biliary complications |
6 |
biliary reconstruction |
6 |
biliary stricture |
6 |
breast cancer |
6 |
carcinoma, hepatocellular - diagnosis - therapy |
6 |
carcinoma, hepatocellular - surgery |
6 |
case-matched study |
6 |
cdk1 inhibitor |
6 |
cholangiocarcinoma |
6 |
cholangiograms |
6 |
cholestasis - etiology |
6 |
close resection margin |
6 |
colorectal liver metastasis |
6 |
complex liver resection |
6 |
controlled study |
6 |
cytokines |
6 |
deceased-donor liver transplantation |
6 |
desmosplastic reaction |
6 |
diagnostic imaging |
6 |
donor hepatectomy |
6 |
duct-to-duct anastomosis |
6 |
ductal anomaly |
6 |
en-bloc resection |
6 |
end-stage liver disease |
6 |
endoscopic retrograde cholangiography |
6 |
endoscopic treatment |
6 |
erc |
6 |
family history |
6 |
graft |
6 |
graft survival |
6 |
graft-weight-to-recipient-weight ratio |
6 |
hepaticojejunostomy |
6 |
hepatoblastoma |
6 |
hepatocellullar carconoma |
6 |
hepatocholangiocarcinoma |
6 |
hepatopancreatoduodenectomy |
6 |
inflammation |
6 |
inflow |
6 |
intrahepatic cholangiocarcinoma |
6 |
invasion |
6 |
keywords |
6 |
laparoscopic resection |
6 |
ldlt |
6 |
liver neoplasms - diagnosis - therapy |
6 |
liver neoplasms - surgery |
6 |
liver resection (lr) |
6 |
liver stiffness |
6 |
liver transplantation (lt) |
6 |
liver transplantation - adverse effects |
6 |
living |
6 |
living donors |
6 |
living-donor liver transplantation |
6 |
metastases |
6 |
modulation |
6 |
neoplasm recurrence, local - surgery |
6 |
nomogram |
6 |
outcome |
6 |
pdx models |
6 |
pediatric donor |
6 |
post-lt surveillance |
6 |
post-transplant recurrence |
6 |
prediction |
6 |
predictive model |
6 |
radiofrequency ablation (rfa) |
6 |
right liver donation |
6 |
right-liver |
6 |
risk factor |
6 |
ro3306 |
6 |
simultaneous resection |
6 |
size |
6 |
small-for-size grafts |
6 |
stage resection |
6 |
standard |
6 |
stereotactic body radiotherapy |
6 |
synchronous colorectal liver metastasis |
6 |
systemic therapy |
6 |
tricuspid annuloplasty |
6 |
tumor recurrence |
6 |
tumour thrombus |
6 |
adefovir |
5 |
adjuvant chemotherapy |
5 |
alpha-fetoprotein (afp) |
5 |
angioplasty - methods |
5 |
anterior approach |
5 |
antitubercular agents - pharmacokinetics - therapeutic use |
5 |
aspartate aminotransferase |
5 |
augmented reality |
5 |
biliary obstruction |
5 |
blunt trauma |
5 |
cancer stem cell |
5 |
chemosensitization |
5 |
complications |
5 |
cyclin d1 |
5 |
deceased-donor liver re-transplantation |
5 |
dose-response relationship, drug |
5 |
double bypass |
5 |
dual portal vein |
5 |
graft failure |
5 |
hepatic artery thrombosis |
5 |
hepatic malignancy |
5 |
hepatitis b virus |
5 |
laparoscopic hepatectomy |
5 |
live donor liver transplantation |
5 |
liver laceration |
5 |
liver remnant |
5 |
liver transplantation - methods |
5 |
liver trauma |
5 |
living-donor liver re-transplantation |
5 |
macrophage polarization |
5 |
malignancy |
5 |
meta-analysis |
5 |
metal stent |
5 |
multiple injuries |
5 |
non-operative management |
5 |
oncological outcomes |
5 |
opportunistic infections - prevention and control |
5 |
pancreatic cancer |
5 |
pancreaticoduodenectomy |
5 |
pancreaticojejunostomy |
5 |
pancreatoduodenectomy |
5 |
pancreatogastrostomy |
5 |
paraganglioma |
5 |
penetrative trauma |
5 |
portal vein - anatomy and histology - surgery |
5 |
portal vein reconstruction |
5 |
post-hepatectomy |
5 |
post-operative complication |
5 |
predicting scoring system |
5 |
pretreatment extent of disease |
5 |
relapse |
5 |
remnant |
5 |
risk stratification |
5 |
single-cell rna sequencing |
5 |
smad inhibitor |
5 |
smad2/3/smad4 |
5 |
surveillance |
5 |
tissue and organ harvesting - methods |
5 |
tuberculosis |
5 |
tuberculosis - diagnosis - drug therapy - transmission |
5 |
tumor heterogeneity |
5 |
vaccination |
5 |
alpha-fetoprotein |
4 |
antibody-mediated rejection |
4 |
associating liver partition and portal vein ligation for staged hepatectomy |
4 |
bilirubin level |
4 |
carcinoma, hepatocellular - mortality - surgery |
4 |
carcinoma, hepatocellular - pathology - surgery |
4 |
carcinoma, hepatocellular - pathology - therapy |
4 |
catheter ablation - methods |
4 |
checkpoint inhibitor |
4 |
chemotherapy |
4 |
cholangiocarcinoma - pathology - surgery |
4 |
cholesterol |
4 |
combined hcc-cc |
4 |
complex liver surgery |
4 |
disease-free survival |
4 |
dyslipidemia |
4 |
ercp |
4 |
fasting glucose |
4 |
grafts |
4 |
hepatectomy - statistics and numerical data |
4 |
hepatitis |
4 |
hepatopancreaticobiliary surgery |
4 |
hilar cholangiocarcinoma |
4 |
icg |
4 |
kidney transplantation |
4 |
left lobe graft |
4 |
lipoprotein |
4 |
liver neoplasms - mortality - surgery |
4 |
liver neoplasms - pathology - surgery |
4 |
liver neoplasms - pathology - therapy |
4 |
mixed tumor, malignant - pathology - surgery |
4 |
orthotopic liver transplantation |
4 |
preoperative biliary drainage |
4 |
radiosurgery |
4 |
right lobe |
4 |
right lobe graft |
4 |
small for size liver graft |
4 |
stereotactic ablative radiation therapy |
4 |
stereotactic radiation therapy |
4 |
survivor |
4 |
technique |
4 |
transplants |
4 |
triglyceride |
4 |
vascular reconstruction |
4 |
vascular resection |
4 |
aclf |
3 |
adenocarcinoma - mortality - pathology - surgery |
3 |
associating liver partition and portal vein ligation for stage hepatectomy |
3 |
cancer |
3 |
colectomy - methods |
3 |
colorectal neoplasms - mortality - pathology - surgery |
3 |
compensatory sweating |
3 |
conversion |
3 |
hepatic resection |
3 |
hepatitis b immune globulin |
3 |
immunoglobulin |
3 |
in-situ split |
3 |
inferior vena cava |
3 |
intensity |
3 |
laparoscopic colectomy |
3 |
laparotomy - statistics and numerical data |
3 |
leiomyosarcoma |
3 |
non-colorectal liver metastasis |
3 |
primary hyperhidrosis |
3 |
resection margin |
3 |
soft tissue sarcoma |
3 |
tenofovir |
3 |
thoracoscopic sympathectomy |
3 |
vena caval tumor |
3 |
acute kidney injury |
2 |
acute liver failure and scute liver failure |
2 |
acute on chronic liver failure |
2 |
anamnesis |
2 |
anatomic landmark |
2 |
anatomic liver resection |
2 |
antineoplastic agents |
2 |
ascites |
2 |
blood clotting |
2 |
case report |
2 |
chronic hepatitis b |
2 |
chronic liver disease |
2 |
colectomy |
2 |
colorectal neoplasms |
2 |
cytoreductive surgical procedures |
2 |
golden window |
2 |
indocyanine green (icg) clearance |
2 |
liver anatomy |
2 |
liver function reserve |
2 |
liver metastases |
2 |
liver neoplasms |
2 |
liver neoplasms/secondary |
2 |
liver neoplasms/surgery |
2 |
magnetic resonance imaging |
2 |
minimally invasive liver surgery |
2 |
multiple organ failure |
2 |
neuroendocrine tumor |
2 |
neuroendocrine tumors/therapy |
2 |
perintoneal neoplasms |
2 |
piro |
2 |
portal vein embolization |
2 |
radiomics |
2 |
sirs |
2 |
surgical resection |
2 |
trans-arterial chemoembolization |
2 |
acrylic resins - adverse effects |
1 |
associating liver partition and portal vein ligation for staged heaptectomy |
1 |
associating liver partition with portal vein ligation for staged hepatectomy |
1 |
biopsy, fine-needle |
1 |
breast |
1 |
breast diseases - etiology - pathology |
1 |
colorectal liver metastases |
1 |
covid-19 |
1 |
cytology |
1 |
endosonography |
1 |
equipoise |
1 |
ethics |
1 |
expanding donor pool |
1 |
expert liver surgeons |
1 |
extended surgery |
1 |
gallbladder cancer |
1 |
high model for end-stage liver disease |
1 |
laparoscopic major hepatectomy |
1 |
mammaplasty - adverse effects - methods |
1 |
mammoplasty |
1 |
minimally invasive donor surgery |
1 |
minimally invasive liver resection |
1 |
pancreatic neoplasms |
1 |
pancreatic pseudocyst |
1 |
patient selection |
1 |
polyacrylamide gel |
1 |
review |
1 |
robotic liver surgery |
1 |
surgical outcomes |
1 |
technical modifications |
1 |
two-stage hepatectomy |
1 |
variability of treatment strategies |
1 |